Literature DB >> 11277392

PCR techniques for clonality assays.

S J Diaz-Cano1, A Blanes, H J Wolfe.   

Abstract

Clonal overgrowths represent the hallmark of neoplastic proliferations, and their demonstration has been proved useful clinically for the diagnosis of malignant lymphomas based on the detection of specific and dominant immunoglobulin and/or T-cell receptor gene rearrangements. Nonrandom genetic alterations can also be used to test clonal expansions and the clonal evolution of neoplasms, especially analyzing hypervariable deoxyribonucleic acid (DNA) regions from patients heterozygous for a given marker. These tests rely basically on the demonstration of loss of heterozygosity (LOH) resulting from either hemizygosity (nonrandom interstitial DNA deletions) or homozygosity of mutant alleles observed in neoplasms. LOH analyses identify clonal expansions of a tumor cell population, and point to monoclonal proliferation when multiple and consistent LOH are demonstrated. Based on the methylation-related inactivation of one X chromosome in female subjects, X-linked markers (e.g., androgen receptor gene) will provide clonality information using LOH analyses after DNA digestion with methylation-sensitive restriction endonucleases. Therefore, both non-X-linked and X-linked analyses give complementary information, related and not related to the malignant transformation pathway respectively. Applied appropriately, these tools can establish the clonal evolution of tumor cell populations (tumor heterogeneity), identify early relapses, distinguish recurrent tumors from other metachronic neoplasms, and differentiate field transformation from metastatic tumor growths in synchronic and histologically identical neoplasms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11277392     DOI: 10.1097/00019606-200103000-00005

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  10 in total

1.  Clonal origin and expansions in neoplasms: biologic and technical aspects must be considered together.

Authors:  Lucia Pozo-Garcia; Salvador J Diaz-Cano
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

2.  Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer.

Authors:  Barbara Domazet; Gregory T Maclennan; Antonio Lopez-Beltran; Rodolfo Montironi; Liang Cheng
Journal:  Int J Clin Exp Pathol       Date:  2008-03-15

3.  Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma.

Authors:  Liang Cheng; Timothy D Jones; Ryan P McCarthy; John N Eble; Mingsheng Wang; Gregory T MacLennan; Antonio Lopez-Beltran; Ximing J Yang; Michael O Koch; Shaobo Zhang; Chong-Xian Pan; Lee Ann Baldridge
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

Review 4.  Complementary analysis of microsatellite tumor profile and mismatch repair defects in colorectal carcinomas.

Authors:  Alfredo Blanes; Salvador J Diaz-Cano
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

5.  Clonal status and clinicopathological observation of cervical minimal deviation adenocarcinoma.

Authors:  Li Gong; Wen-Dong Zhang; Xiao-Yan Liu; Xiu-Juan Han; Li Yao; Shao-Jun Zhu; Miao Lan; Yan-Hong Li; Wei Zhang
Journal:  Diagn Pathol       Date:  2010-04-24       Impact factor: 2.644

6.  The identification of monoclonality in fibrous dysplasia by methylation-specific polymerase chain reaction for the human androgen receptor gene.

Authors:  Masae Mikami; Hirotaka Koizumi; Masamitsu Ishii; Hisaya Nakajima
Journal:  Virchows Arch       Date:  2003-10-24       Impact factor: 4.064

7.  Molecular genetic evidence for different clonal origins of epithelial and stromal components of phyllodes tumor of the prostate.

Authors:  Ryan P McCarthy; Shaobo Zhang; David G Bostwick; Junqi Qian; John N Eble; Mingsheng Wang; Haiqun Lin; Liang Cheng
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 8.  Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design.

Authors:  Salvador J Diaz-Cano
Journal:  Int J Mol Sci       Date:  2012-02-13       Impact factor: 6.208

Review 9.  Pathological bases for a robust application of cancer molecular classification.

Authors:  Salvador J Diaz-Cano
Journal:  Int J Mol Sci       Date:  2015-04-17       Impact factor: 5.923

Review 10.  Clinical implications of intratumor heterogeneity: challenges and opportunities.

Authors:  Santiago Ramón Y Cajal; Marta Sesé; Claudia Capdevila; Trond Aasen; Leticia De Mattos-Arruda; Salvador J Diaz-Cano; Javier Hernández-Losa; Josep Castellví
Journal:  J Mol Med (Berl)       Date:  2020-01-22       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.